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Proton therapy is a radiotherapy modality that can offer a better physical dose 
distribution when compared to photon radiotherapy by taking advantage of the Bragg peak, a 
narrow region of rapid energy loss. Proton therapy is also known to offer an enhanced relative 
biological effectiveness (RBE) compared to photons. In the current clinical standard, RBE is 
fixed at 1.1 at all points along the proton beam, meaning protons are assumed to require 10% 
less dose than photons to achieve target coverage and organ at risk (OAR) sparing. However, 
there is mounting clinical evidence, and a significant number of in vitro experiments, that show 
RBE varies, typically as a function of dose averaged linear energy transfer (LETD). 
There are two goals of this work. The first is to develop a novel method to model proton 
RBE by using the microdosimetric kinetic model (MKM). The MKM requires a quantity called 
dose mean lineal energy (𝑦𝑦𝐷𝐷), which is analogous to LETD, to model RBE. In this work, a novel 
method to calculate 𝑦𝑦𝐷𝐷 is proposed, based on the proton energy spectrum at a location, and 
Monte Carlo simulations of microdosimetry. The second goal of this work is to implement 
MKM into a treatment planning system to assess the theoretical clinical impact of including 
variable RBE during treatment plan optimization.   
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This work presents a method to calculate 𝑦𝑦𝐷𝐷 and model the RBE of several proton RBE 
experiments. The variable RBE of these experiments was modeled more accurately by MKM 
than previously proposed phenomenological models. However, a clear superiority over an 
LETD-based model was not demonstrated. In a treatment planning exercise, including variable 
RBE modeling into the optimization algorithm led to increased target coverage while 
maintaining the dose sparing of OARs. Based on the parameters chosen for the MKM, this led 
to an increase in physical dose delivered to the brainstem, and when reanalyzed assuming an 
RBE = 1.1, led to doses beyond tolerance. In conclusion, this work presents a novel method to 
compute 𝑦𝑦𝐷𝐷 for input into the MK model, and demonstrates slight potential benefits of 
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Chapter 1: Introduction  
 
1.1 Proton therapy 
Proton therapy is a radiotherapy treatment modality whereby protons are accelerated to 
high energies and then used to irradiate a tumor. Robert Wilson, a physicist at Harvard 
University, first proposed proton therapy in 1946 [1]. Wilson proposed that protons be used for 
therapy due their unique physical characteristic, the Bragg peak. As protons are transported 
through a medium, they gradually lose energy. This energy loss is quantified by stopping power 
S. After the proton has lost most of its initial kinetic energy, stopping power rapidly increases 
with continued energy loss, until all kinetic energy is lost. The rapid increase in stopping power 
results in the Bragg peak, a narrow region with large amounts of energy deposited. Wilson 
proposed that several proton energies be used to create a spread-out Bragg peak (SOBP), which 
can provide adequate dose distribution across a target volume. A schematic comparing single 
Bragg peaks, a spread out Bragg peak and the depth-dose curve for an MV photon beam is 
shown in Fig. 1. When comparing the depth-dose curve of protons to photons the physical 
advantage of protons becomes clear. Photon beams are characterized by having a dose peak at 
relatively shallow depths with a long “tail” that extends beyond the depth of the patient. The 
physical nature of photons means there is significant dose to tissue upstream and downstream 
from the target. Contrast this to a proton SOBP, which results in rapid dose fall off over a few 
millimeters at the beam’s distal edge. Theoretically this means that a critical structure such as 



























1.2 Relative biological effectiveness 
There is also a radiobiological rationale for using proton therapy: protons have an 
increased biological effectiveness compared to photons. This is quantified with relative 
biological effectiveness (RBE), defined as the ratio of doses for two different radiation types to 
Figure 1: Comparison of proton and photon depth-dose 
curves.   
Multiple pristine Bragg peaks (blue solid lines) are irradiated 
onto a target to achieve a spread out Bragg peak (blue dashed 
line). The various heights of the pristine beams indicate each 
beam is given a different weight to ensure a flat SOBP. This 
image “Comparison_of_dose_profiles_for_proton_v._x-







reach the same biological endpoint. Convention dictates that the reference radiation dose goes in 







Currently in clinical practice, proton RBE is assumed to be 1.1 at all points along the Bragg 
curve. However Paganetti showed, according to most cell survival experiments, RBE values for 
proton therapy vary along the Bragg curve. RBE in the entrance region is ~1.1, rising to ~1.15 
in the Bragg peak and SOBP, and increasing to ~1.35 in the distal edge and ~1.7 in the distal 
falloff region [2]. While wide variations in RBE are observed, Paganetti concluded that on 
average, for most of the Bragg curve, the RBE has a value of ~1.1. RBE is typically modeled as 
a function of dose-averaged linear energy transfer (LETD), a physical quantity that is 
straightforward to calculate with Monte Carlo simulations such as GATE [3, 4], FLUKA [5], 
GEANT4 [6] or TOPAS [7] or analytical functions [8, 9]. Clinical proton beams typically have 
LETD values that reach a maximum around 20-25 keV/µm. In this range, most data show a 
linear relationship of RBE as a function of LETD [10]. As summarized by Grün et al, most 
RBE(LETD) experiments have been measured in regions where the LET distribution is relatively 
narrow [11]. However, as noted by Grün et al and Mohan et al, in regions such as an SOBP or 
overlapping fields, the LET distribution may be broad and the RBE(LETD) relationship is no 
longer linear [11, 12].  
 Clinical evidence of variable proton RBE is scarce but concerning. Peeler et al analyzed 
a set of pediatric ependymoma patients who had T2-FLAIR hyperintensity regions in MR 
images after proton therapy and showed that these regions are highly correlated with increased 
LET, and therefore increased RBE [13].  A paper published after the National Cancer Institute 
(NCI) hosted a workshop on radiobiological issues in charged particle therapy noted that as the 
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number of patients treated with proton therapy increases, so do the reports of unexpected 
toxicities [14]. In another NCI workshop, brainstem injuries in pediatric patients undergoing 
proton therapy were discussed and recommendations were made for modifying treatment plans 
in order to reduce these injuries [15].  Underwood et al showed in a cohort of lung cancer 
patients receiving proton therapy that RBE exceeded 1.1 based on follow up CT scans that 
showed increased lung tissue density [16]. These examples should make it clear that the topic of 
proton biological effectiveness should be further studied, and eventually should be taken into 
account when creating the proton treatment plans of the future.   
1.3 Scope of Dissertation and Specific Aims 
In current clinical practice, the relative biological effectiveness (RBE) of proton beams 
is assumed to be 1.1 at all points along the Bragg curve. However, several recent experiments 
have shown that the RBE of therapeutic proton beams can be as high as 2 or greater in the 
region distal to the Bragg peak [17-19]. This RBE is significantly different than the standard 
clinical practice of using a constant RBE of 1.1, meaning the tissue in the region distal to the 
Bragg peak is receiving significantly more damage. At present, there has been limited work 
showing that the microdosimetric kinetic model (MKM) can be used to predict such high RBEs 
in proton therapy.  
Accurate prediction of the RBE at each point along the Bragg curve would enable 
biologically-optimized treatment plans, which have the potential to offer improved treatments 
for proton therapy patients. By quantifying the RBE at all points along the proton beam, clinical 
physicists will be able to place the most damaging parts of the beam within the target and take 
full advantage of proton therapy’s biological dose distribution.  MKM is a first-principle model 
that predicts cell survival based on dose deposition on a scale of micrometers, and has been used 
to model carbon ion RBE, but has not yet been applied clinically to proton therapy. The central 
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goal of this project is to determine how well MKM can accurately predict RBE in the high LET 
region of the proton beam and to develop a treatment planning system that implements MKM to 
predict proton RBE. The following Specific Aims will address this central goal:  
Aim One: Evaluate the accuracy of phenomenological RBE models in the Bragg peak and 
distal falloff region. Several RBE models have already been proposed, which typically model 
RBE as a linear function of LET. However, recent RBE data shows strong evidence that RBE 
may in fact be a nonlinear function of LET, especially beyond the Bragg peak. The hypothesis 
for this Aim is: in the high linear energy transfer (LET) region at and beyond the Bragg peak, 
phenomenological RBE models will underestimate RBE by at least 20%. This Aim will 
determine the applicability of phenomenological RBE models in the high LET region and 
possibly demonstrate the need for a model that accurately predicts the high RBEs in these 
regions. 
Aim Two: Optimize the microdosimetric parameters to achieve a best fit for observed RBE data 
based on the MKM. I propose a method to calculate microdosimetric quantities that uses the 
proton energy spectrum at various locations along the Bragg curve, based on calculations using 
the Geant4 DNA toolkit. The method will be tested with three data sets, consisting of seven total 
experiments across three different proton beamlines. I hypothesize this MK model will predict 
the RBEs at all points along the proton beam, including the Bragg peak and distal falloff 
regions, within experimental uncertainties. This Aim will also obtain the optimal parameters for 
fitting MKM to experimental data, demonstrating the best fit achievable using MKM.  
Aim Three: Develop a variable RBE prediction functionality in a treatment planning system for 
proton therapy. The goal of this Aim is to implement the MKM into matRad, an open-source 
treatment planning system that allows the user to access all radiation calculations and even add 
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their own functionalities to the software. Successful completion of this Aim would enable a 
treatment planning system to biologically optimize a proton therapy treatment plan, a feature 
needed clinically, but not yet developed. Treatment plans optimized using a variable RBE will 
be compared to those optimized with a constant 1.1 RBE to investigate whether variable RBE 
plans can improve the therapeutic ratio.  
The work described above will develop a method for using experimental biological data 
and microdosimetry to predict RBE in a treatment planning system for proton therapy. In 
current proton therapy treatment, variable RBE is not considered, likely resulting in an over-
dosing of tissues at and distal to the Bragg peak. This project is innovative in that it seeks to 
bring variable RBE prediction into clinical use, a capability that has not been realized, and has 
the potential to lead to better patient outcomes by placing the most biologically damaging 








Chapter 2: Methods and Materials  
 
This chapter is based upon a paper reprinted from International Journal of Radiation 
Oncology*Biology*Physics, Vol. 104, Issue 2, Mark Newpower, Darshana Patel, Lawrence 
Bronk, Fada Guan, Pankaj Chaudhary, Stephen J. McMahon, Kevin M. Prise, Giuseppe 
Schettino, David R. Grosshans, Radhe Mohan, Using the Proton Energy Spectrum and 
Microdosimetry to Model Proton Relative Biological Effectiveness, Pages 316-324 Copyright 




2.1 RBE Data 
The RBE data used in this work have been previously published by Chaudhary et al, 
Guan and Bronk et al and Patel and Bronk et al [17-19].  In each of these three data sets the 
authors performed cell survival experiments and fit the clonogenic cell survival data for protons 
and photon beams with the linear quadratic (LQ) model. These model parameters were then 
used to calculate RBE at various cell survival levels (i.e. 10%, 50%, etc.). These experiments 
were performed on three different beamlines: at the Proton Therapy Center Houston (PTCH) at 
MD Anderson Cancer Center [18], at Centro di AdroTerapia Applicazioni Nucleari Avanzate 
(CATANA) in Catania, Italy [17], and at the Heidelberg Ion Therapy Center (HIT) in 
Heidelberg, Germany [19]. For each experiment the LETD was calculated at each RBE 
measurement point to enable modeling RBE as a function of LETD. The experiments by Guan 
and Bronk et al and Patel and Bronk et al were done only along a pristine Bragg peak, while 
Chaudhary et al used both a pristine Bragg peak and an SOBP for their experiments. Four cell 
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lines were utilized in these studies: AGO1522 and U87 (Chaudhary et al), H460 and H1437 
(Guan and Bronk et al), while Patel and Bronk et al performed a very similar RBE experiment 
to Guan and Bronk et al, with only H460 cells. The 𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 values for each study are 
presented in Table 1. For all RBE calculations in this work, RBE was calculated at the 10% 
clonogenic survival level.  
Table 1: 𝜶𝜶𝒙𝒙 and 𝜷𝜷𝒙𝒙 parameters for RBE data. 
The 𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 parameters shown here were taken from the 
RBE studies. These values are used an input in RBE model 
calculations.  
Cell line 𝜶𝜶𝒙𝒙 [Gy-1] 𝜷𝜷𝒙𝒙 [Gy-2] 
Guan and Bronk et al [18]   
H460 0.290 0.083 
H1437 0.05 0.041 
Patel and Bronk et al [19]   
H460 0.290 0.083 
Chaudhary et al [17]   
AGO1522 0.54 0.062 
U87 0.110 0.06 
 
2.2 RBE models 
Despite Paganetti’s conclusion that RBE should remain fixed at 1.1 for now, there is 
mounting clinical evidence that assuming an RBE = 1.1 in treatment planning leads to image 
changes along the proton beam’s distal edge. Peeler et al. showed these MR image changes are 
well correlated with high LET regions in children treated for ependymoma [13]. Underwood et 
al. demonstrated the distal edge region of the proton beam corresponds to increased Hounsfield 
Unit changes in CT scans of lung patients following radiation therapy, and linked these changes 
to an RBE > 1.1 [16]. Therefore there is a clinical interest in understanding how RBE varies 
along the path of the proton beam. If clinical physicists were able to model a variable RBE in 
the treatment planning system, then treatment plans could be optimized to deliver high RBE 
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radiation to the target tissue and spare normal tissue with low RBE radiation. Several 
phenomenological RBE models have been proposed [20] and three are summarized below.   
The model proposed by Wedenberg et al [21] assumes a constant value for β, while α is 
linearly dependent on LETD, a fitting parameter 𝑞𝑞 and the x-ray α/β ratio (α/β )𝑥𝑥:  
 






The value for 𝑞𝑞 was found by fitting across 10 cell lines and has a value of 0.434 Gy µm/keV. 
The value for 𝑞𝑞 is assumed to be the same regardless of cell type or the physical characteristic of 
the proton beam. Wedenberg et al caution, however, that this equation is not valid for LETD 
higher than 30 keV/ µm.   
 The RBE model proposed by Carabe-Fernandez et al takes into account RBE’s 
dependence on LET in the 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑝𝑝 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑥𝑥 terms and is also based on the LQ model [22, 
23]. The coefficients in the model’s 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑝𝑝 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑥𝑥 terms were determined via linear 
regression of previously published RBE experiments.  This RBE model also requires as input 
the physical proton dose, which will be set to 1.8 Gy throughout this work.   
 











































McNamara, Schuemann and Paganetti [24] developed an RBE model based on the 
concepts of 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑝𝑝 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑥𝑥 proposed by Carabe et al [22] as well as on a dependence on 
�(α/ β )𝑥𝑥 proposed by Jones [25]. Like the Carabe-Fernandez model, this model requires the 
physical proton dose as input, and is set to 1.8 Gy throughout this work. The McNamara et al 
model has the form:  
 










































The fitting coefficients 𝑝𝑝0 − 𝑝𝑝3 were found to be: 𝑝𝑝0= 0.999064 (standard error) (SE) 0.014125, 
𝑝𝑝1= 0.35605 (SE 0.015038), 𝑝𝑝2= 1.1012 (SE 0.0059972), and 𝑝𝑝3= -0.0038703 (SE 0.00091303), 
with a R2 value of 0.255. The McNamara model was shown to predict RBE values well at low 
LETD. However at higher LETD values (~18.7 keV/µm), the model predicts a lower RBE than 
measured experimentally by Guan and Bronk et al.  
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To facilitate comparison to the microdosimetric kinetic model (MKM) a generic LETD 
based model with a single fitting parameter was proposed: 
 𝛼𝛼𝑝𝑝 =  𝛼𝛼𝑥𝑥 + 𝑘𝑘 × 𝐿𝐿𝑅𝑅𝐿𝐿𝐷𝐷 (7) 
   
This model assumes 𝛽𝛽 is constant for both proton and X-ray beams. The 𝑘𝑘 parameter was varied 
to achieve a best fit with the experimental RBE data. This generic RBE model enabled a 
comparison to the MKM because both models have one free fitting parameter. The method to 
compare the MKM and generic RBE model is outlined in section 2.5.  
A first-principle approach to predicting cell survival known as the microdosimetric 
kinetic model (MKM) was proposed by Hawkins [26, 27]. His work built upon the theory of 
dual radiation action, developed by Kellerer and Rossi, and Zaider and Rossi [28, 29]. As its 
name implies, MKM uses the concepts of microdosimetry, the study and quantification of 
spatial and temporal distributions of absorbed energy in irradiated matter [30, 31]. The central 
concept of microdosimetry is the domain, a spherical volume of unit density. The radius of the 
domain (𝑟𝑟𝑑𝑑) is typically on the order of 0.5 µm. The domain is defined as the distance a DNA 
lesion can travel through the nucleus before it is repaired [27]. Thus, the domain is a cell-
specific parameter that depends on the cell’s ability to repair damage to its DNA. If the domain 
is placed randomly near an ion track, there is a probability that energy will be deposited inside 
it. The simplest microdosimetric quantity is specific energy 𝑧𝑧, which has units of J/kg, or Gray, 
and can be considered as a stochastic equivalent of absorbed dose [30]. Specific energy can be 
averaged in two ways: frequency-averaged and dose-averaged, 𝑧𝑧𝐹𝐹 and 𝑧𝑧𝐷𝐷, respectively. Another 
quantity of interest is lineal energy 𝑦𝑦, which is defined as the quotient of the energy deposited 
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into the domain 𝜀𝜀 by a primary particle, with mean chord length 𝑙𝑙 through that volume, 






Lineal energy has units of keV/µm. In the same way as specific energy, the lineal energy 
frequency distribution function can be used to calculate frequency averaged (𝑦𝑦𝐹𝐹) and dose 
averaged (𝑦𝑦𝐷𝐷) lineal energy. The single event distributions of specific energy (𝑓𝑓(𝑧𝑧)) and lineal 
energy (𝑓𝑓(𝑦𝑦)) are used to compute frequency and dose averaged specific and lineal energy in 
the following way: 
 























The quantity 𝑦𝑦𝐷𝐷 is particularly important in the MK model when used to model ion irradiation 
survival experiments. It is the stochastic quantity in microdosimetry that corresponds to LETD. 
Both LETD and 𝑦𝑦𝐷𝐷 are used as measures of radiation quality and as a surrogate for biological 
response. For proton therapy studies this work used the MKM equations presented by Kase et al 
[32]. The MKM follows the linear-quadratic model with 𝛼𝛼 and 𝛽𝛽 coefficients for dose and the 
square of the dose, respectively. The MKM is written as follows 
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 ln(𝑆𝑆𝑆𝑆) = 𝛼𝛼𝐷𝐷 + 𝛽𝛽𝐷𝐷2 (13) 
 




 𝛽𝛽𝑝𝑝 =  𝛽𝛽𝑥𝑥 (15) 
where 𝑆𝑆𝑆𝑆 is the survival fraction, 𝑦𝑦𝐷𝐷 is the dose-mean lineal energy, 𝜋𝜋 is the mass density of 
water and the subscripts 𝑝𝑝 and 𝑥𝑥 denote protons and x-rays, respectively. The MKM assumes 
that regardless of the radiation type, the 𝛽𝛽 term is constant. The MK model assumes that 𝛼𝛼0 is 
the slope of the survival curve in the limit of LET =0, but in this work, 𝛼𝛼𝑥𝑥 is used rather than 𝛼𝛼0, 
as the reference radiation 𝛼𝛼 parameter. LET for the reference radiation is assumed to be low 
enough that 𝛼𝛼 variations for the reference radiation is negligible, making 𝛼𝛼0 appropriate.  
2.3 Calculating 𝒚𝒚𝑫𝑫 and fitting MKM to experimental data 
To input microdosimetric values such as 𝑦𝑦𝐷𝐷 into the MKM, they must be measured, such 
as with a tissue-equivalent proportional counter (TEPC) or calculated. This subchapter will 
propose a method to calculate 𝑓𝑓(𝑦𝑦) using the Geant4 DNA toolkit. Then a method to calculate 
𝑦𝑦𝐷𝐷 based on the proton energy spectrum and lineal energy probability density functions (𝑓𝑓(𝑦𝑦)) 
will be presented. Finally the least-squares fitting of the MK model to experimental data will be 
described. 
2.3.1 Computational Resources 
All Monte Carlo and Matlab computations done in this work were performed on either 
the Nautilus or Seadragon clusters at the MD Anderson Cancer Center. The Nautilus cluster had 
over 300 compute nodes, and each node was a BL465c G7 blade with two 12-core AMD 6174 
processors, for a total of 12 cores per node. Each code had at minimum, 64 GB RAM. 
Nautilus’s operating system was Red Hat Enterprise Linux 6.5 with a queueing interface 
consisting of PBS/Torque and Moab. Seadragon is MD Anderson’s newest cluster, consisting of 
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204 compute nodes with 27 CPU cores per node, and 192 GB RAM per node. Seadragon uses 
Red Hat Enterprise 7.4 as its operating system and uses the Spectrum Load Sharing Facility 10.1 
software for job scheduling.   
2.3.2 Geant4 DNA 
The DNA extension to the Geant4 Monte Carlo simulation toolkit is designed to enable 
modeling of ionizing radiation at the scale of DNA in liquid water [6, 33-36]. In order to model 
radiation interactions with matter on the scale of nanometers, unique particle physics models 
have been developed for increased accuracy at low energies, on the order of hundreds of eV. 
These models are essential to calculate the energy loss of protons at low, although relevant 
energies for proton therapy around 1 MeV. As with any Monte Carlo system, the settings for the 
simulation are important. This work used all the default settings provided in the Geant4 DNA 
10.2.0 release, except for the secondary particle range cut value. This range cut refers to the 
minimum range a secondary particle must have in order to be transported by the Monte Carlo 
code. If an ionized electron has a range below the cut value the electron and all its kinetic 
energy is deposited locally without being transported. For protons with kinetic energies > 2 
MeV, the cut length was left at 1000 nm. For protons ≤ 2 MeV the cut length was set to 5 nm. 
The different cut lengths will be explained in section 2.3.3. Simulations were created to 
transport protons through a cube of liquid water with 5 µm side lengths. 295 proton energies 
were simulated, with up to 100 unique tracks simulated per energy. The range of energies for 
protons was [0.1, 223] MeV, which covered the energy spectrum of the proton machine at the 
Proton Therapy Center Houston. The output of the simulation included, for all primary and 
secondary particles, the position in 3 dimensions, kinetic energy, event type, and parent track. 
This allowed the reconstruction of the path and kinetic energy of the primary proton through the 
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water cube, as well as the path and kinetic energies of all ionized electrons and other secondary 
particles.  
2.3.3 Calculating 𝑦𝑦 and 𝑓𝑓(𝑦𝑦) 
A Matlab script was developed to take the output of the Geant4 DNA and reconstruct the 
3D map of the proton’s track through the water cube, along with the position and energy of 
secondary particles. The script placed spheres with radii of 500 nm at random points at and 
along the proton track. The script determined if energy was deposited into a sphere, and how 
much, computing 𝜀𝜀 from Eq. 8. The mean chord length 𝑙𝑙 was calculated via Cauchy’s formula to 
be   
 𝑙𝑙 = 4(𝑉𝑉/𝑆𝑆) (16) 
 
where 𝑉𝑉 is the volume and 𝑆𝑆 is the surface area of the sphere. Thus for each randomly-placed 
sphere the lineal energy deposited in that sphere was calculated. The scored 𝑦𝑦 values were then 
binned, with a range of [0.01, 300] keV/µm and 0.1 keV/µm bin widths. The result of these 
binned lineal energy values is a histogram, which is the function 𝑓𝑓(𝑦𝑦) for that proton energy. 
Because the 𝑦𝑦 values scored 𝑛𝑛 times were used to compute 𝑦𝑦𝐷𝐷, which is a sum over all scored 
values according to Eq. 12, the fractional error in each bin was assumed to follow a Poissonian 
distribution: 
 





The total fractional error for the 𝑓𝑓(𝑦𝑦) of a single proton energy was the quadrature sum of the 
fractional error of each lineal energy bin. The total number of scored spheres were increased 
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until the total maximum fractional error for any 𝑓𝑓(𝑦𝑦) was < 1.5 × 10-4 for protons <100 MeV. 
For protons with energies > 100 MeV the number of samples per track was set to 500.  
For protons with energies > 2 MeV, the vast majority of ionized electrons had kinetic 
energies that enabled them to travel further than 1000 nm, the default cut length in the Geant4 
DNA “dnaphysics” example. However for protons ⪅ 2 MeV, a significant fraction of ionized 
electrons did not have enough kinetic energy to go beyond 1000 nm, but did have enough 
energy to travel beyond the 500 nm radius of the domain, and thus the Geant4 code deposited 
the kinetic energy of the particle locally. The result of using the 1000 nm cut length for protons 
with energies ≥ 2 MeV were 𝑦𝑦𝐷𝐷 values that were 2-3 times greater than what was expected, 
based on previously published work by Nikjoo et al and Lindborg et al [37] [38]. Based on these 
results, all track files for proton energies ≥ 2 MeV were re-simulated and the lineal energy and 
𝑓𝑓(𝑦𝑦) re-calculated. The resulting 𝑦𝑦𝐷𝐷 values then agreed much closer to Nikjoo et al and 
Lindborg et al’s values.  
2.3.4 Calculating 𝑦𝑦𝐷𝐷 of a polyenergetic proton beam  
The rate that an ion loses kinetic energy in a micrometer sized volume is not constant. 
Rather, it follows a probability distribution 𝑓𝑓(𝑦𝑦). This stochastic nature of energy loss must be 
accounted for in microdosimetry, hence the use of averaged quantities such as 𝑦𝑦𝐷𝐷. In the case of 
a proton beam passing through a patient, particularly at the Bragg peak, the 𝑦𝑦𝐷𝐷 value includes 
energy loss characteristics of a broad energy distribution. It is with this understanding that the 
following method for calculating 𝑦𝑦𝐷𝐷 was conceived. For each energy 𝑖𝑖, by weighting the 
constituent 𝑓𝑓(𝑦𝑦)𝑚𝑚 by its fluence 𝛷𝛷(𝑅𝑅)𝑚𝑚 at a particular point, the probability density function of a 

















2.4 Fitting 𝒓𝒓𝒅𝒅 and calculating RBE 
Once 𝑦𝑦𝐷𝐷  was calculated, the radius of the domain 𝑟𝑟𝑑𝑑 from Eq. 14 was varied to reach the 
best agreement with the experimental RBE. The best 𝑟𝑟𝑑𝑑 was found using the least squares 
method when RBE is modeled as a function of  𝑦𝑦𝐷𝐷 . The value of 𝑟𝑟𝑑𝑑 was expected to vary by 
only 200-300 nm at most, and such a difference in the domain size compared to the calculated 
𝑦𝑦𝐷𝐷  using 𝑟𝑟𝑑𝑑 = 500 nm via Geant4 DNA will not change the underlying  𝑓𝑓(𝑦𝑦) distribution 
significantly. Thus it was appropriate to use the 𝑓𝑓(𝑦𝑦) values calculated with Geant4 DNA. To 
calculate the RBE of the MK model Eq. 20 was used: 
 
𝑅𝑅𝑅𝑅𝑅𝑅 =
�𝛼𝛼𝑥𝑥2 − 4𝛽𝛽𝑥𝑥 𝑙𝑙𝑛𝑛 𝑆𝑆𝑆𝑆 − 𝛼𝛼𝑥𝑥






The subscripts 𝑝𝑝 and 𝑥𝑥 in Eq. 20 refer to proton and X-ray 𝛼𝛼 and 𝛽𝛽 parameters, respectively. 
𝛼𝛼𝑝𝑝 and 𝛽𝛽𝑝𝑝 are calculated from Eq. 14 and 15, and  𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 are from the LQ fitting parameters 
of the reference X-ray radiation. 𝑆𝑆𝑆𝑆 refers to the survival fraction of the clonogenic cell survival 
experiments, and was set to 0.1 in this work. Eq. 20 was obtained by solving for the dose terms 





2.5 Comparing RBE models 
The hypothesis of Specific Aim One was phenomenological RBE models will under-
predict RBE by 20% in the Bragg peak and distal falloff region. The percentage difference 
between the RBE model and experimental data was calculated by Eq. 21: 
 





 The generic RBE model in Eq. 7 uses LETD as a measure of radiation quality. Authors 
such as Mohan et al [12] and Grün et al [11] have argued that dose-averaged LET may not be 
the most reliable indicator of biological effect. They argue that in theory, for a proton beam with 
a broad energy distribution such as that found near and distal to the Bragg peak, the low energy 
(and thus high LET) portion of the proton energy spectrum will kill cells more efficiently than 
the higher energy (and thus lower LET) portion. Averaging LET values based on dose could 
lead to breakdowns in the assumed linear relationship between LET and RBE. A comparison of 
MKM, with its radiation quality measured by 𝑦𝑦𝐷𝐷 and the generic RBE model with radiation 
quality in LETD would be useful to determine if one model is superior to the other. The Akaike 
Information Criterion (AIC) analysis method quantitatively compared the MKM with the 
generic RBE model. AIC analysis compares two models used to fit data and determines which 
of the two models fits better based on their respective sum of squares. Eq. 22 and Eq. 23 express 
how the relative likelihood (𝑅𝑅𝐿𝐿) that the worse-fitting model better represents the data is 
calculated. The terms 𝑆𝑆𝑆𝑆1 and 𝑆𝑆𝑆𝑆2 are the sum of squares from each model fit. The values for 
𝑆𝑆𝑆𝑆1 and 𝑆𝑆𝑆𝑆2 were chosen so that 𝑆𝑆𝑆𝑆2 > 𝑆𝑆𝑆𝑆1. In Eq. 22 𝑁𝑁 is the number of experimental RBE 
points to compare the models to.  
 








 𝑅𝑅𝐿𝐿 = exp (−∆𝐴𝐴𝐴𝐴𝐴𝐴/2 ) 
 
(23) 
2.6 matRad  
MatRad is a treatment planning system written in Matlab [39]. It enables the user to 
create optimized radiotherapy treatment plans with photons and ions such as protons and 
carbon. MatRad includes functions for a graphical user interface (GUI),  to import DICOM CT 
data, to optimize treatment plans based on dose objectives, and for carbon ions, it includes a 
biological optimization option which uses the LEM IV model [40]. A screenshot of the matRad 
GUI is shown in Fig. 2. Due to being written in Matlab the entire code is open source and the 
user can modify the underlying functions as they wish. MatRad also supports users creating 
their own beamlines. For this work, the matRad code used for this work was downloaded on 
April 5, 2018. Matlab R2017b was used to run matRad. The scanning beamline in use at PTCH, 
known as G3, was commissioned into matRad. The data for G3 was taken from Monte Carlo 
data that was validated against measurements. G3 has 94 proton beam energies, from 72.5 MeV 







There are significant concerns for brainstem toxicities in patients with ependymoma receiving 
proton radiotherapy [13-15]. In theory, the smaller the (α/β )𝑥𝑥 ratio is, the greater the RBE [2, 
23]. As expressed by Lühr et al, tissues most affected by variable RBE should be late 
responding tissues (low (α/β )𝑥𝑥 ratio) that receive low to intermediate doses and are located 
distal to the target [42]. The brainstem is just such a critical structure and thus, an ependymoma 
patient planning CT would make an ideal test case to investigate the efficacy of optimizing 
treatment plans using a variable RBE.  
 2.6.1 Incorporating MKM optimization into matRad 
The MK model requires the calculation of 𝑦𝑦𝐷𝐷 to compute 𝛼𝛼𝑝𝑝 and therefore RBE (Eqs. 
12, 14, 20). Based on the number of voxels in a modern treatment planning CT (~10-20 ×106) it 
Figure 2: matRad GUI 
MatRad has many of the basic functionalities of commercial treatment planning systems, 
including defining optimization settings. The treatment plan shown comes standard with the 




is not computationally feasible to compute the proton energy spectrum in each voxel and apply 
Eq. 19 to calculate RBE during the optimization process, which can require hundreds of 
RBE×Dose calculations. Therefore the method to calculate RBE by Inaniwa et al for carbon 
beam therapy in Japan was adopted for this work [43]. In their paper, Inaniwa et al adopted the 
MK model proposed by Kase et al by calculating 𝑧𝑧1𝐷𝐷∗ , or the saturation-corrected dose mean 
specific energy of the domain delivered in a single event [32]. Carbon ion therapy requires a 
saturation correction for LETs > ~150 keV/μm, where RBE reaches a maximum and further 
increases in LET result in a decreasing RBE, called the overkill effect. This overkill effect is not 
present in proton therapy and therefore there needs to be no saturation correction for a treatment 
planning system using the MK model for proton therapy. In the paper by Inaniwa et al 𝑧𝑧1𝐷𝐷∗  was 
calculated by combining the contributions from individual carbon beamlets: 
 
(𝑧𝑧1𝐷𝐷 𝑚𝑚𝑚𝑚𝑥𝑥∗ )𝑚𝑚 =  
∑ 𝑤𝑤𝑗𝑗 ∙ 𝑑𝑑𝑚𝑚𝑗𝑗 ∙ (𝑧𝑧1𝐷𝐷∗ )𝑚𝑚𝑗𝑗
𝑁𝑁𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑗𝑗=1





where (𝑧𝑧1𝐷𝐷∗ )𝑚𝑚𝑗𝑗 is the saturation-corrected dose mean specific energy of the domain at position 𝑖𝑖 
delivered by beam 𝑗𝑗, and 𝑁𝑁𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝is the number of beam spots in the treatment plan. 𝑤𝑤𝑗𝑗 represents 
the weight of spot 𝑗𝑗 and 𝑑𝑑𝑚𝑚𝑗𝑗 is the dose at point 𝑖𝑖 from beam 𝑗𝑗.  During optimization, the values 
of 𝑤𝑤𝑗𝑗are varied to achieve target coverage and organ at risk (OAR) sparing. The approach 
implemented into matRad followed this same calculation in Eq. 24, except 𝑦𝑦𝐷𝐷 was be calculated 
instead of 𝑧𝑧1𝐷𝐷∗ . From Kase et al, 𝑧𝑧1𝐷𝐷 (the dose mean specific energy, not saturation corrected) is 
related to 𝑦𝑦𝐷𝐷 by:  
 




where 𝑟𝑟𝑑𝑑 is the radius of the domain. In this work the dose mean lineal energy of a mixed proton 




�𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥�𝑚𝑚  =  
∑ 𝑤𝑤𝑗𝑗 ∙ 𝐷𝐷𝑚𝑚𝑗𝑗 ∙ (𝑦𝑦𝐷𝐷 )𝑚𝑚𝑗𝑗
𝑁𝑁𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑗𝑗=1





In matRad the dose to a point 𝑖𝑖 from pencil beam 𝑗𝑗 is calculated by the matrix multiplication of 
the dose influence matrix 𝐷𝐷𝑚𝑚𝑗𝑗and the weight 𝑤𝑤 of pencil beam 𝑗𝑗. Casting this as a matrix vector 
product 𝒅𝒅�⃗ = 𝐷𝐷𝒘𝒘���⃗  takes advantage of Matlab’s speed in matrix multiplication, where  𝒅𝒅�⃗ is the a 
vector with the dose to every voxel, from every beam. Therefore including the (𝑦𝑦𝐷𝐷 )𝑚𝑚𝑗𝑗 term in 
Eq. 26 was conceptually straightforward.  
 To implement the 𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥 calculation, the 𝑦𝑦𝐷𝐷 at each depth for every proton beam 
energy must be calculated. To do this, the proton energy spectrum at 1 mm intervals in depth, 
for all 94 beams in G3 was simulated using a MCNPX model of the beamline [44]. The 𝑦𝑦𝐷𝐷 at 
every mm was calculated using Eq. 18 and Eq. 19, using the 𝑓𝑓(𝑦𝑦) calculated from Geant4 DNA 
simulations presented in sections 2.3.2 and 2.3.3. The results of these calculations were saved in 
a file called yD_table_MDA_G3.mat for later use in calculating 𝑦𝑦𝐷𝐷 at a given depth for every 
beam energy. Figure 3 shows a screenshot of the yD_table_MDA_G3.mat data. The public 
version of matRad does not currently feature the ability to incorporate variable RBE in proton 
treatment plan optimization. However this functionality was added by modifying the matRad 
source code. In the default dose calculation function called 
matRad_calcParticleDose.mat, the dose from every pencil beam to every voxel in the 
planning CT is calculated. By default, this data is not available to the user, as the total dose to 
all voxels from all beams is the output of the function. A copy of 
matRad_calcParticleDose.mat called 
matRad_calcParticleDose_MKM_optimization.mat was created in order to save, as 







beam’s contribution to the total dose in a voxel, which is used in Eq. 26. During the 
optimization process, the vector of weights (𝑤𝑤𝑗𝑗) of each pencil beam 𝑗𝑗 was varied until the dose 
constraints and objectives were solved to an acceptable level. For each iteration the function 
matRad_calcParticleDose_MKM_optimization.mat  was called because as the pencil 
beam weights changed, each pencil beam’s dose contribution to a voxel changed. The process to 
recalculate the dose contributions from each pencil beam to each voxel takes approximately two 
to four minutes, and is a major contributor to the slowness of the MKM optimization process in 
matRad.  
Figure 3: yD_table_MDA_G3.mat format 
This data table enables the calculation of 𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥 for the 
G3 beamline. 𝑦𝑦𝐷𝐷 values as a function of depth are 
interpolated based on this data. There is also an entry for 
the maximum depth of the beam. All 𝑦𝑦𝐷𝐷 values beyond 
this depth are set to 0.  
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The MKM optimization functionality written into matRad is summarized as follows. 
Inside the optimization function, a function called matRad_backProjection.mat is called 
to calculate the current dose distribution, which is then evaluated via the optimizer’s objective 
function for conformity to plan constraints and objectives. matRad_backProjection.mat 
calls MKM_RBE_Calculator.mat which then calls  
matRad_calcParticleDose_MKM_optimization.mat, which calculates the dose 
contribution from each pencil beam to every voxel. The output of this function is a data 
structure called dij_MKM. This is then used as input into a function called 
yD_doseAvg_calculation_beams.mat was written to calculate �𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥�𝑚𝑚 according to Eq. 
26. This function in turn called calculateProtonRBEFromyD.mat, a function written to 
calculate the RBE in all voxels of the planning CT. The output of 
calculateProtonRBEFromyD.mat is a matrix named MKM_RBE_cube with dimensions 
𝑋𝑋 × 𝑌𝑌 × 𝑍𝑍, where 𝑋𝑋, 𝑌𝑌, and 𝑍𝑍 are the number of voxels in the planning CT in the respective 
coordinate axes. MKM_RBE_cube was then multiplied by the physical dose distribution to get 
the RBE-weighted dose (RWD) distribution. The RWD distribution was then evaluated for 
adherence to the dose constraints and objectives. This process was repeated until the dose 
constraints and objectives were met. Fig. 4 is a flowchart of the optimization process. For this 
project MKM_RBE_Calculator.mat, yD_doseAvg_calculation_beams.mat and 
calculateProtonRBEFromyD.mat were newly written functions, while 
matRad_backProjection.mat and 
matRad_calcParticleDose_MKM_optimization.mat were functions provided by 







2.6.2 Patient data  
As presented in section 1.2 and Refs 13-15, there are significant concerns about 
brainstem toxicities with pediatric ependymoma patients. The treatment planning CT from a 
patient treated at the PTCH was used to evaluate the clinical effect of incorporating variable 
RBE as calculated by the MK model into intensity modulated proton therapy (IMPT) treatment 
plans. The patient was treated on the G3 scanning beamline. The OAR and target contours and 
simulation CT were imported into matRad. The beam angles chosen in matRad were identical to 
those used for treatment at PTCH, and consisted of three beams. Gantry angles were 110°, 180° 
Figure 4: RBE optimization implemented into matRad. 
This flowchart demonstrates the implementation of calculating RBE via the MK model in 
matRad. Functions called by the optimization process end in .m, and are shown in black 




and 250°, and the couch angle for each beam was 0°. The distance between spots was set to 9 
mm. Planning objectives in matRad were guided by constraints given in Table 2. The GTV was 
prescribed 1.8 Gy(RBE) per fraction for 30 fractions, for a total target prescription of 54 
Gy(RBE) to the GTV.  The constraints and dose prescriptions are the same as those used by a 
current MD Anderson internal trial for ependymoma patients.  
Table 2: Organ at risk constraints for ependymoma patients. 
OAR Constraint  
Optic nerves (ON) Max ≤ 55 Gy(RBE) 
Optic chiasm (OC) Max ≤ 55 Gy(RBE) 
Brainstem  D10% < 55.4 Gy(RBE)  
D50% < 52.4 Gy(RBE)  
V50 < 61.7% 
V55 < 17.7%  
D0.1cc < 56.6 Gy(RBE) 
Spinal cord Max ≤ 50 Gy(RBE) 
Eye, including retina Max 45 Gy(RBE) 
 
Once all the dose constraints were met, and the GTV received as close to 100% of the 54 
Gy(RBE) prescription dose as possible without exceeding OAR tolerance doses, the treatment 
plan was deemed acceptable for MKM optimization. The equivalent uniform dose (EUD) to the 
brainstem was then calculated and the normal tissue complication probability (NTCP) 
computed, using the parameters outlined in section 2.6.3.  
2.6.3 Radiobiological properties of tissues during MKM optimization 
The 𝛼𝛼0  and 𝛽𝛽 values for each tissue were the same ones assigned by Frese et al in their 
RBE analysis, which was taken from a PhD dissertation by Cronqvist [45, 46]. 𝛼𝛼0 is used rather 
than 𝛼𝛼𝑥𝑥 to be consistent with the MKM laid out by Kase et al, where 𝛼𝛼0 is the initial survival 
curve slope in the limit of LET=0. The 𝛼𝛼0 values presented by Frese are corrected from the 𝛼𝛼𝑥𝑥 
values by assuming LET in the experiments from which 𝛼𝛼𝑥𝑥 was determined is approximately 
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0.5 keV/μm. Using either 𝛼𝛼0 or 𝛼𝛼𝑥𝑥 is assumed to have a negligible effect on the RBE value.  
Therefore the α/β ratios given in Table 3 are not exactly 10 Gy or 2 Gy, but slightly less. 
However the 𝛼𝛼𝑥𝑥/ 𝛽𝛽𝑥𝑥 ratio given by Frese are exactly 10 Gy or 2 Gy. The value for 𝑟𝑟𝑑𝑑 in the GTV 
and CTV was set to 243 nm. This was chosen based on the fitted value for the AGO1522 cell 
line in the SOBP irradiations. AGO1522 has an α/β ratio of 8.7 Gy, which is the closest 
experimental value to the assumed tumor α/β ratio of 10 Gy. For all other tissues, since they 
have an α/β ratio of 2 Gy, 𝑟𝑟𝑑𝑑 was set to 461 nm. This is also based on fitting a cell line, in this 
case the U87 SOBP experiment, as the U87 α/β ratio is 1.83 Gy. Table 3 gives the assumed 
parameters used during RBE calculations in this work.  
Table 3: Radiobiological properties of tissues for RBE optimization 
Tissue α/β (Gy) 𝜶𝜶𝟎𝟎 (Gy-1) 𝜷𝜷 (Gy-2) 
Tumor (GTV, CTV) 10 0.1084 0.0112 
Brainstem 2 0.0492 0.0266 
Spinal cord 2 0.0367 0.0203 
Optic nerves 2 0.0256 0.0471 
Optic chiasm 2 0.0256 0.0471 
Eyes 2 0.0367 0.0203 
Brain 2 0.0580 0.0310 
 
To estimate the normal tissue complication probability (NTCP) for the brainstem, 
equivalent uniform dose (EUD) and Niemierko’s NTCP/TCP model was used [47] [48]. EUD is 











where 𝑣𝑣𝑚𝑚 is the 𝑖𝑖’th volume receiving dose 𝐷𝐷𝑚𝑚, and 𝑠𝑠 is a unitless parameter that corresponds to 
the tumor or normal tissue. NTCP is calculated by  
 





In Eq. 28, 𝐿𝐿𝐷𝐷50 corresponds to the tolerance dose that results in 50% of a population 
experiencing a complication, and 𝛾𝛾50 is a parameter that describes the slope of the dose-
response curve, and is unique to each tissue. Using the NTCP/TCP tool published by Gay and 
Niemierko, brainstem EUD and NTCP were calculated [49]. Setting the 𝑠𝑠 parameter in the EUD 
calculation to a large positive number will skew the EUD towards the maximum dose to a 
structure. The maximum dose is important to a serial organ such as the brainstem, as the most 
difficult planning constraint to meet is to keep the dose to 0.1 cc of the brainstem below 56.6 
Gy(RBE). Thus for brainstem EUD, the 𝑠𝑠 = 25. As recommended by Niemierko, 𝛾𝛾50 was set to 
4 and TD50 was set to 65 Gy [49].  
2.6.4 Comparing standard treatment plans to MKM optimized plans 
To assess the impact of including variable RBE during treatment plan optimization, a 
treatment plan optimized using the standard RBE=1.1 paradigm was compared to a treatment 
plan optimized using the MK model for variable RBE. A radiation oncologist reviewed these 
plans and deemed them clinically realistic. Treatment plan DVHs and NTCPs for the brainstem 
will be compared. There will be three DVHs and three NTCPs; one each from the std_opt, 
std_opt_MKM_calc, and MKM_opt plans. These plans are defined in the workflow below: 
29 
 
1) Patient planning CT, OARs and target contours are imported into matRad. Optimization 
objectives are also set.  
2) A treatment plan assuming a constant RBE=1.1 is created and optimization objectives 
varied until OAR constraints are met and the plan is approved by a radiation oncologist 
as clinically realistic. This standard treatment plan is saved and is known as the std_opt 
plan.  
3)  The variable RBE using MKM is calculated on std_opt. The variable RBE result is then 
saved as well. This is known as the std_opt_MKM_calc plan.  
4) The variable RBE, MKM-calculated standard treatment plan (std_opt_MKM_calc) is 
used as the starting point for an MKM-optimized treatment plan. This resulting MKM-
optimized plan is then saved. This plan is known as the MKM_opt plan.  
One purpose of this workflow was to first create a realistic treatment plan with the RBE=1.1 
model (std_opt) and then calculate the variable RBE and RWD (std_opt_MKM_calc) to 
evaluate the potential dangers in using a constant RBE. RWD hot spots are expected in critical 
structures such as the brainstem and spinal cord, and in normal brain tissue. The second purpose 
of this workflow was to take the std_opt_MKM_calc plan and optimize it using a variable RBE 
calculated via the MK model. It is hypothesized that by including the MK model in the 
optimization algorithm, another clinically realistic treatment plan can be created (MKM_opt) 
that should both increase target coverage and reduce normal issue toxicity as compared to the 





Chapter 3: Results 
 
This chapter is based upon a paper reprinted from International Journal of Radiation 
Oncology*Biology*Physics, Vol. 104, Issue 2, Mark Newpower, Darshana Patel, Lawrence 
Bronk, Fada Guan, Pankaj Chaudhary, Stephen J. McMahon, Kevin M. Prise, Giuseppe 
Schettino, David R. Grosshans, Radhe Mohan, Using the Proton Energy Spectrum and 
Microdosimetry to Model Proton Relative Biological Effectiveness, Pages 316-324. Copyright 




3.1 Phenomenological model fitting to experimental RBE data 
The phenomenological models proposed by Wedenberg et al [21], Carabe-Fernandez et 
al [22], and McNamara et al [24] were applied to the RBE datasets previously published by 
Chaudhary et al [17], Guan and Bronk et al [18] and Patel and Bronk et al [19]. The LQ model 
parameters used for each cell line are given in Table 1. Fig. 5 shows the RBE models with the 
data from Guan and Bronk et al and Chaudhary et al. Fig. 6 shows the RBE models with the 





Figure 5: Phenomenological and generic RBE models applied to the Chaudhary et al 
and Guan and Bronk et al data.  
Panels a and b show the RBE models and the two cell line data published in Ref. 18. 
Panels c-f show the RBE models and cell line data published in Ref. 17. Error bars on 








3.2 Difference between phenomenological RBE models and RBE data 
The Bragg peak in the Guan and Bronk et al data occurs near the LETD = 10.8 keV/µm 
data point, meaning the four highest LET values are in the Bragg peak and distal falloff regions. 
Tables 4 and 5 show the results of the phenomenological models’ accuracy in modeling the data 
from Guan and Bronk et al.  
 
 
Figure 6: Models applied to RBE data from Patel and Bronk et al 
Phenomenological proton RBE models applied to RBE data published by Patel and Bronk 




Table 4: Guan and Bronk et al H460 data compared to phenomenological RBE models.  
The predicted RBE values for each of the three phenomenological RBE models are given, as 
well as the percent difference between the models and experimental RBE. A percent difference 
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer, 
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN: 
McNamara RBE model; CF: Carabe-Fernandez RBE model.  
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
10.8 1.28 1.48 -14% 1.47 -13% 1.53 -16% 
15.2 1.87 1.69 11% 1.61 16% 1.72 9% 
17.7 2.58 1.81 43% 1.69 53% 1.82 42% 
19 3.28 1.89 74% 1.74 89% 1.87 75% 
  
Table 5: Guan and Bronk et al H1437 data compared to phenomenological RBE models. 
The predicted RBE values for each of the three phenomenological RBE models are given, as 
well as the percent difference between the models and experimental RBE. A percent difference 
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer, 
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN: 





Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
10.8 1.26 1.35 -7% 1.63 -23% 1.78 -29% 
15.2 1.7 1.52 12% 1.81 -6% 2.02 -16% 
17.7 2.33 1.62 44% 1.91 22% 2.15 8% 
19 2.98 1.67 78% 1.69 76% 2.21 35% 
 
In the data from Chaudhary et al, the Bragg peak in the pristine Bragg peak experiments 
occurs at the LETD=11.8 keV/µm data point. Table 6 shows the results of the phenomenological 
model fittings of the pristine Bragg peak experiments. Chaudhary et al also included RBE 
experiments done in an SOBP. The most proximal point in the SOBP was where LETD = 2.6 
keV/µm. The results of phenomenological model fittings for the Chaudhary et al SOBP data are 
shown in Table 7. The Bragg peak in the Patel and Bronk et al data occurs closest to the 
LETD=9.8 keV/µm point. Table 8 shows the results of the phenomenological RBE model 




Table 6: Chaudhary et al pristine Bragg peak data compared to phenomenological RBE 
models. 
The predicted RBE values for each of the three phenomenological RBE models are given, as 
well as the percent difference between the models and experimental RBE. A percent difference 
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer, 
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN: 
McNamara RBE model; CF: Carabe-Fernandez RBE model.  
Pristine Bragg Peak, AGO1522 Cell Line 
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
11.9 2.45 1.37 79% 1.3 88% 1.3 88% 
18 2.66 1.56 71% 1.44 85% 1.48 80% 
22.6 3.38 1.72 97% 1.54 119% 1.61 110% 
 
Pristine Bragg Peak, U87 Cell Line 
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
11.9 1.42 1.48 -4% 1.62 -12% 1.75 -19% 
18 1.84 1.77 4% 1.85 -1% 2.04 -10% 

















Table 7: Chaudhary et al SOBP peak data compared to phenomenological RBE models. 
The predicted RBE values for each of the three phenomenological RBE models are given, as 
well as the percent difference between the models and experimental RBE. A percent difference 
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer, 
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN: 
McNamara RBE model; CF: Carabe-Fernandez RBE model.  
SOBP, AGO1522 Cell Line 
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
2.6 1.44 1.08 34% 1.09 32% 1.01 43% 
4.5 1.69 1.13 49% 1.13 50% 1.07 58% 
13.4 1.93 1.41 37% 1.34 44% 1.35 43% 
21.7 2.24 1.69 33% 1.52 47% 1.59 41% 
25.9 2.75 1.83 50% 1.61 71% 1.70 61% 
 
SOBP, U87 Cell Line 
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
2.6 1.11 1.09 2% 1.20 -8% 1.20 -8% 
4.5 1.18 1.17 1% 1.30 -9% 1.33 -11% 
13.4 1.27 1.55 -18% 1.68 -24% 1.82 -30% 
21.7 1.44 1.95 -26% 1.98 -27% 2.21 -35% 
25.9 1.64 2.17 -24% 2.12 -23% 2.38 -31% 
 
Table 8: Patel and Bronk et al H460 data compared to phenomenological RBE models. 
The predicted RBE values for each of the three phenomenological RBE models are given, as 
well as the percent difference between the models and experimental RBE. A percent difference 
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer, 
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN: 
McNamara RBE model; CF: Carabe-Fernandez RBE model.  
LETD Exp. 
RBE 
Wed % diff from 
Exp. RBE 
McN % diff from 
Exp. RBE 
CF % diff from 
Exp. RBE 
9.8 1.39 1.43 -2% 1.43 -3% 1.48 -6% 
12.3 1.47 1.55 -5% 1.51 -3% 1.59 -8% 
13.8 1.75 1.62 8% 1.57 12% 1.66 6% 
15.2 1.78 1.69 5% 1.61 10% 1.72 3% 
16.8 1.96 1.77 11% 1.66 18% 1.79 10% 
18.9 2.20 1.88 17% 1.73 27% 1.87 18% 




3.3 Fractional error of Geant4 DNA 𝒇𝒇(𝒚𝒚) scoring method 
Due to the stochastic nature of energy deposition on the micrometer scale, the method 
for calculating 𝑓𝑓(𝑦𝑦) for each proton energy as outlined in Chapter 2.3.3 is subject to uncertainty. 
This uncertainty was quantified with fractional error as expressed in Eq. 17. For this work, 295 
proton energies were simulated and their 𝑓𝑓(𝑦𝑦) calculated. The proton energy range for this data 
set is [0.1, 223.0] MeV, which covers the relevant energy range for proton therapy performed at 
the PTCH.  Fig. 7 shows the fractional error for each calculated 𝑓𝑓(𝑦𝑦) and the number of scored 
spheres per track to reach that fractional error. Protons with kinetic energies < 100 MeV had a 
maximum fractional error of 1.5 × 10-4, while protons with kinetic energy > 100 MeV had a 






Figure 7: Fractional Error, samples per track, and number of tracks sampled using Geant4 DNA 
Panel a) shows the total fractional error in each calculated 𝑓𝑓(𝑦𝑦), by using the number of sampled domains per track, 
given in panel b). Panel c) shows the total number of tracks used to calculate 𝑓𝑓(𝑦𝑦). The discontinuities at 100 MeV 
in panels a) and c) are a result of different ionization models used by Geant4 DNA. The transition from one model 





3.4 Calculating 𝒚𝒚𝑫𝑫  
Fig. 8 shows 𝑦𝑦𝐷𝐷 for each of the 𝑓𝑓(𝑦𝑦) calculated via Eq. 19. The plot in Fig. 8 thus 
represents the calculated 𝑦𝑦𝐷𝐷 for a purely monoenergetic proton beam. A comparison of these 𝑦𝑦𝐷𝐷 
values and those published by Nikjoo et al [37] was made by Newpower et al [50], and they 
concluded the 𝑦𝑦𝐷𝐷 between the two studies were very similar, particularly at low proton energies. 
The comparison is shown in Fig. 8. In each of the three RBE studies used as experimental data 
in this work, the authors calculated the proton energy spectrum at each RBE measurement point. 
These spectra were used as input for Eq. 18 and the dose mean lineal energy (𝑦𝑦𝐷𝐷) was calculated 
via Eq. 19. The results of these calculations are shown in Fig. 9. The linear relationship between 










Figure 8: 𝒚𝒚𝑫𝑫 values for monoenergetic proton beams 
The 𝑦𝑦𝐷𝐷 for each calculated 𝑓𝑓(𝑦𝑦), based on Eq. 12. The discontinuity at 100 MeV 
is an artifact of changing ionization models at 100 MeV. The 𝑦𝑦𝐷𝐷 published in 









Figure 9: Relationship between 𝒚𝒚𝑫𝑫 and LETD 
The relationship between radiation qualities 𝑦𝑦𝐷𝐷 and LETD. A linear 
relationship between the two radiation qualities was expected. This 
figure is used with Permission from Elsevier.  
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3.5 Modeling RBE with the generic RBE model and the MK model 
The generic RBE model from Eq. 7 was fit to the experimental data by varying 𝑘𝑘 and 
inputting the LQ parameters listed in Table 1. By varying 𝑟𝑟𝑑𝑑 and using the  𝑦𝑦𝐷𝐷 calculated via Eq. 
18 and Eq. 19 and using the LQ parameters from Table 1, the experimental RBE data was 
modeled by the MK model. The results of these fittings is presented in Figs. 10-12. In the panels 
of these figures are the fitted 𝑘𝑘 and 𝑟𝑟𝑑𝑑 values. Note that in Figs. 10-12, the abscissa is plotted as 
LETD. This is to remain consistent with convention, but the reader should be aware that for the 






Figure 10: Generic RBE model and MK model applied to Guan and Bronk et al data 
Panel a) shows the results of the model fittings for the H460 cell line and panel b) shows the 










Figure 11: Generic RBE model and MK model applied to Chaudhary et al data. 
Panels a) and b) show the U87 cell line experiments and model fittings in the pristine 
Bragg peak and spread out Bragg peak setups, respectively. Panels c) and d) show the 
same fittings for the same irradiation setups with the AGO1522 cell line. Used with 










3.6 AIC analysis of generic RBE model vs. the MK model 
Table 9 shows the results of the AIC analysis to compare the performance of the generic 
RBE model and MK model. The relative likelihood from the AIC analysis is the likelihood that 
the worse-fitting model (in terms of a larger sum of squares) is actually the better model. MKM 




Figure 12: Generic RBE model and MK model applied to Patel and Bronk et al 
data. 
The H460 RBE experiment performed by Patel and Bronk et al. Used with 




Table 9: AIC analysis of generic RBE model vs MK model  
Results of the AIC analysis comparing the generic RBE model to the MK model. 
The RL indicates the relative likelihood that the worse-fitting model actually is 
superior. SS indicates the sum of squares difference between the data and the 
model fit.  
Cell line        MKM Generic 





𝑟𝑟𝑑𝑑 = 323 nm k=0.0621 
CI=[286.7-379.3] CI = [0.04798-0.07578] 
SS1 = 1.473 SS2 = 1.061 
RL = 0.140 - 
H1437 𝑟𝑟𝑑𝑑 = 310 nm k=0.0330 
CI = [274.8-368.8] CI = [0.02511-0.04073] 
SS1 = 1.271 SS2 = 0.9396 
RL = 0.1632 - 
Chaudhary et al 




𝑟𝑟𝑑𝑑 = 302 nm k=0.08423 
CI=[192.4-213.9] CI=[0.07092-0.09746] 
SS2=0.1096 SS1=0.2404 
 - RL = 0.0948 
Pristine Bragg peak, 
U87 
𝑟𝑟𝑑𝑑=345 nm k=0.0285 
CI=[311.3-394.7] CI=[0.02554-0.0313] 
SS1=0.1189 SS2=0.02386 
RL = 0.0081 - 
Spread out Bragg 
peak, AGO1522 
𝑟𝑟𝑑𝑑=243 nm k=0.0537 
CI=[227.2-262.8] CI=[0.03957-0.06765] 
SS2=0.1086 SS1=0.3402 
- RL = 0.0325 
Spread out Bragg 
peak, U87 
𝑟𝑟𝑑𝑑= 461 nm k=0.0147 
CI=[420.0-518.0] CI=[0.01318-0.0194] 
SS2=0.02759 SS1=0.01614 
RL = 0.2002 - 
Patel and Bronk et al 𝑟𝑟𝑑𝑑 = 426 nm k = 0.045 
H460 CI=[397.5-461.9] CI=[0.03987-0.0514] 
 SS1 = 0.3606 SS2 = 0.2169 




3.7 matRad Optimization Results 
In order to compute RBE for the MK model, 𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥 must be calculated, which requires 
the 𝑦𝑦𝐷𝐷 of each beam contributing dose at that location. Figure 13 shows an example of the 𝑦𝑦𝐷𝐷 
and integral depth doses for two beams, 88.0 MeV and 181.1 MeV, and is illustrative of the data 
used for MKM optimization in matRad.  
Following the constraints given in Table 2 and the dose prescription of 54 Gy(RBE) to 
the GTV, a treatment plan using RBE=1.1 was created, known as the std_opt plan. The RBE-
weighted dose (RWD) was recalculated on this treatment plan using the MK model outlined in 
section 2.6.1, and is called the std_opt_MKM_calc plan. Finally, a biologically optimized plan 
known as MKM_opt was created. Table 10 shows the GTV and CTV coverage as well as the 
dose to the brainstem and spinal cord and NTCP estimates for the brainstem for each plan.  
Figure 14 shows the DVHs for the std_opt and std_opt_MKM_calc plans. This shows 
that hot spots in normal brain tissue appeared, and cold spots appeared in the brainstem when 
analyzing the std_opt plan with a variable RBE calculated via the MK model.  
During optimization, the dose must be rapidly recalculated for each iteration. In the 
standard optimization algorithm (fixed RBE=1.1), each recalculation of the dose and objective 
function took approximately 1-3 seconds. During the MK model based optimization, each dose, 
RBE and objective function calculation took approximately 6-7 minutes. When running the 
RBE optimization algorithm, a typical optimization run would take ~6-17 hours, and require a 




Figure 15 shows the RBE distribution of the std_opt_MKM_calc plan. In most of the 
brainstem, RBE < 1.1. This is what led to the lower EUD and lower point doses to the brainstem 
on the std_opt_MKM_calc plan as shown in Table 10.  
Hotspots appeared at the edge of the CTV and in the normal brain tissue just beyond the 
CTV when the variable RBE was calculated on the std_opt plan. Figure 16 shows the same CT 
slice with a side by side comparison of the std_opt plan and the std_opt_MKM_calc plan. The 
hotspot was reduced in the MKM_opt plan, and the result is shown in Fig. 17. The hotspot in the 
CTV was reduced, as was the RWD in the region just outside of the CTV.  
Table 10: Dose to targets and OARs for IMPT plans 
The doses to the optic chiasm, optic nerves and eyes were well below tolerances and are not 
shown.  
Structure/EUD std_opt std_opt_MKM_calc MKM_opt  
% of  GTV getting ≥ 54 Gy(RBE) 88.0 87.7 94.0  
GTV EUD [Gy(RBE)] 57.0 57.8 58.3  
% of CTV getting ≥ 54 Gy(RBE) 74.1 76.8 76.9  
Max spinal cord dose [Gy(RBE)] 49.7 49.0 47.5  
Dose to 10% of brainstem [Gy(RBE)] 54.6 52.2 54.0  
Dose to 50% of brainstem [Gy(RBE)] 47.6 45.2 46.3  
Dose to 0.1cc of the brainstem [Gy(RBE)] 56.2 55.8 56.0  
Brainstem EUD [Gy(RBE)] 52.2 51.1 51.7  









Figure 13: IDDs and 𝒚𝒚𝑫𝑫 as a function of depth for two beams. 
The 𝑦𝑦𝐷𝐷  of the beams only increases rapidly near and beyond the Bragg peak. 
The bump at 140 mm is an artifact of different ionization models used by 










Figure 14: Dose volume histograms of the RBE-weighted doses of the std_opt and 
std_opt_MKM_calc plan. 
The dashed lines indicate the resulting DVHs when the IMPT plan was optimized using the 
constant RBE=1.1 model. Solid lines are the DVHs of that same physical dose distribution 













Figure 15: RBE in the brainstem, GTV and CTV as calculated by the MKM 
Based on the values for 𝛼𝛼0, 𝛽𝛽, and 𝑟𝑟𝑑𝑑, the RBE in the brainstem was mostly < 1.1. This 
led to decreased RWD to the brainstem when the RBE is calculated from the MK model 






Figure 16: Comparison of std_opt to std_opt_MKM_calc 
The RWD distribution for the std_opt plan is shown in panel a. By calculating the variable RBE via MKM, on the std_opt dose 
distribution, a hotspot in the CTV appeared (Panel b). There was also an increased RWD region outside of the CTV, as compared to the 







Figure 17: MKM optimization plan reduces RWD brainstem hotspot 
This dose colorwash shows how the RWD in the brainstem is reduced through the MKM-optimized treatment plan. In panel a the RWD 
from std_opt_MKM_calc is shown. In panel b is the same location on the MKM_opt plan. The hotspot in the CTV has been reduced, and 




Figure 18 compares the DVHs of the std_opt_MKM_calc plan to the MKM_opt plan. 
This shows increased GTV coverage as well as increased RWD to the brainstem in the 
MKM_opt plan. In Figure 19 the 𝑦𝑦𝐷𝐷 distribution from the std_opt plan (calculated in the 
std_opt_MKM_calc plan) is shown next to the 𝑦𝑦𝐷𝐷 distribution in the MKM_opt plan. 𝑦𝑦𝐷𝐷 was 
reduced in the brainstem and maintained in the GTV and CTV after RBE optimization. Figure 
20 shows the physical dose difference between the MKM_opt plan and the std_opt plan. This 
figure demonstrates the dose modulation that occurred during the RBE optimization process, 
and shows that physical dose was increased into the brainstem and decreased in the GTV and 
CTV. 
The RWD distribution in the MKM_opt plan was recalculated with the RBE=1.1 model, 
and the DVH of the MKM_opt plan with variable and fixed RBE (RBE=1.1) is shown in Fig. 
21. Dose-volume parameters of this recalculation are shown in Table 11. To obtain the RWD of 
the MKM_opt plan for the RBE=1.1 model, the physical dose in the MKM_opt plan was 











Figure 18: DVH comparison of std_opt_MKM_calc and MKM_opt 
In this DVH comparison, the solid lines represent the MKM_opt plan and the dashed lines 
the std_opt_MKM_calc plan. Note that in this figure, the std_opt_MKM_calc plan is in 













Figure 19: 𝒚𝒚𝑫𝑫 distribution before and after MKM optimization 
Panel a shows the 𝑦𝑦𝐷𝐷 distribution in the brainstem, GTV and CTV as calculated on the std_opt plan. Panel b shows the 𝑦𝑦𝐷𝐷  distribution after 








Figure 20: Difference in physical dose distributions between std_opt and MKM_opt plan 
Both panels show the difference in physical dose in the two optimized plans, std_opt and MKM_opt. The slice in panel a is the same slice 
shown in Fig. 15, and the slice in panel b is the same slice shown in Figs. 16, 17 and 19. During the optimization process in the 
MKM_opt plan, the physical dose in the brainstem was increased, and the physical dose in the GTV and CTV was decreased by several 






Table 11: DVH metrics for MKM optimized plan analyzed with variable RBE and RBE=1.1 
Summary of the DVH metrics of the MKM_opt plan with the variable RBE, and with the 
MKM_opt variable RBE with the RWD recalculated using a constant RBE=1.1.  
Structure/EUD MKM_opt, Variable RBE MKM_opt, RBE=1.1 
% of  GTV getting ≥ 54 Gy(RBE) 94.0 77.5 
GTV EUD [Gy(RBE)] 58.3 55.9 
% of CTV getting ≥ 54 Gy(RBE) 76.9 59.3 
Max spinal cord dose [Gy(RBE)] 47.5 48.6 
Dose to 10% of brainstem [Gy(RBE)] 54.0 56.8 
Dose to 50% of brainstem [Gy(RBE)] 46.3 48.4 
Dose to 0.1cc of the brainstem [Gy(RBE)] 56.0 59.1 
Brainstem EUD [Gy(RBE)] 51.7 55.6 











Figure 21: RWD for MKM_opt plan and MKM_opt plan recalculated with RBE = 1.1 
The solid lines represent the DVH for the MKM_opt plan (same as the solid lines in Fig. 18). 
The dashed lines represent the DVH for the RWD of the MKM_opt plan by assuming RBE = 




Chapter 4: Discussion 
 
4.1 Difference between phenomenological models and experimental RBE data 
The phenomenological proton RBE models proposed by Wedenberg et al, McNamara et 
al and Carabe-Fernandez et al were applied to experimental data published by Chaudhary et al, 
Guan and Bronk et al and Patel and Bronk et al. These model fittings are shown in Fig. 5 and 
Fig 6. The percent difference between model predictions and experimental data are shown in 
Tables 4-8. The purpose of applying these phenomenological proton RBE models to these 
experiments was to determine how well the models predict RBE in the Bragg peak and distal 
falloff region.  
For both cell lines in the Guan and Bronk et al data the phenomenological models 
overestimated RBE close to the Bragg peak, around 10.8 keV/µm, but the models 
underestimated RBE at higher LETD (Fig. 5a, 5b). As remarked by McNamara et al and Guan 
and Bronk et al, this experimental data shows RBE as a highly nonlinear function of LETD [18, 
24]. All three of the presented models fail to account for the nonlinearity of this data set and 
therefore no models even follow the same shape as the data. The three models’ accuracy in the 
H460 cell line experiments underestimated RBE by greater than 20% only at the highest two 
LETD points.  The H1437 data was similarly modeled by the phenomenological models, where 
RBE underestimation by the models was for the highest two LETD points. The exception to this 
was the Carabe-Fernandez model, which overestimated RBE at the Bragg peak by 29%, and 
was within 8% at the 17.7 keV/µm LETD point. In conclusion the phenomenological RBE 
models poorly model the RBE data in presented by Guan and Bronk et al.  
In contrast to the striking nonlinearity of the Guan and Bronk et al data, all of the data 




between RBE and LETD (Fig. 5 c-f, Fig. 6). The AGO1522 cell line in both the SOBP and 
pristine Bragg peak configuration was not modeled well by the phenomenological models. Each 
model under predicted RBE in the Bragg peak and beyond, with up to 110% difference between 
the Carabe-Fernandez model and experimental data. In the SOBP the AGO1522 cells (Fig. 5e) 
were better modeled by the phenomenological models, although in all cases the models 
underestimate RBE by more than 20%. AGO1522 is a normal human fibroblast cell line with a 
large (8.7 Gy) α/β ratio. Many malignant tumors are radioresistant and thus have smaller α/β 
ratios, and these results show the dangers in assuming the same radiobiological properties across 
a range of tissues.  Ideally, different radiobiological survival parameters should be applied to 
different tissues in treatment planning. The U87 cell line is a radioresistant glioma cell line, and 
the phenomenological RBE models predict RBE much better with the U87 cells than the 
AGO1522 cells. In the pristine Bragg peak setup on the U87 cells (Fig. 5d), the RBE models 
actually overestimate RBE in the low LETD region, but are typically within 10%. In the U87 
SOBP setup (Fig. 5f) the RBE models also overestimate RBE, typically by more than 20%. 
Overall, phenomenological models do not model the RBE as function of LETD well, save for the 
U87 pristine Bragg peak geometry.  
In Fig. 10 and Table 8 the comparison of the phenomenological RBE models and RBE 
data is presented for the Patel and Bronk et al data. This dataset uses the same cell line, H460, as 
presented in Guan and Bronk et al. However the data by Patel and Bronk do not show the same 
degree of nonlinearity between RBE and LETD.  The reason for the differences in the two 
experiments is unclear, but can possibly be related to differences in cell colony counting during 
the clonogenic assays between the two studies, and the different Monte Carlo simulation 
settings between the two studies. Whatever the cause, the Patel and Bronk et al RBE as a 




were done at or beyond the Bragg peak. All three phenomenological models overestimate RBE 
for the points closest to the Bragg peak (9.8 and 12.3 keV/µm). After this point RBE models 
underestimate RBE. However at only the highest LETD point (20.2 keV/µm) do the RBE 
models underestimate the experimental RBE by more than 20%.   
4.2 Fitting the generic RBE model to data 
The generic RBE model fit the experimental RBE data well, except for the very 
nonlinear data published by Guan and Bronk et al. In the Chaudhary et al data, the generic RBE 
model fits the pristine Bragg peak data better than the SOBP data, due to that data’s more linear 
relationship between LETD and RBE. The generic RBE model and the MK model fittings are 
shown in Figs. 10-12. Overall, by fitting the generic RBE model to the data, RBE is modeled 
well as a linear function of LETD. 
4.3 Uncertainty analysis of Geant4 DNA 𝒇𝒇(𝒚𝒚) scoring method 
The uncertainty analysis of the presented Geant4 DNA scoring method to calculate 𝑓𝑓(𝑦𝑦) 
(Fig. 7) shows that with enough samples and enough proton tracks, a small amount of fractional 
error can be assured. The fractional errors for every 𝑓𝑓(𝑦𝑦) below 1 × 10-3 for protons means that 
when 𝑓𝑓(𝑦𝑦) functions are combined as in Eq. 19, the combined fractional error of all the 
individual 𝑓𝑓(𝑦𝑦) will be negligible. In Fig. 7c) the number of simulated proton tracks drops from 
100 to about 70 and gradually decreases as energy increases. This is due to the change in 
physics models mentioned in section 4.4. The physics models used for protons with kinetic 
energies > 100 MeV assume that the protons interact with matter much less frequently than the 
models used below 100 MeV. Thus when some simulations are carried out by Geant4 DNA, the 
result is that the proton had no interactions in the 5 µm sided water cube, and therefore no track 
file was written. This was discovered during post-processing of the data. Due to the relatively 




simulate this data is supported by the minimal effects these higher energy protons have on the 
RBE calculation in the treatment planning cases, as discussed in section 4.7.   
4.4 Calculating 𝒚𝒚𝑫𝑫 
The method to calculate 𝑓𝑓𝑤𝑤(𝑦𝑦) in Eq. 18 is a novel method to calculate 𝑓𝑓𝑤𝑤(𝑦𝑦) based on a 
fluence-weighted averaging of constituent 𝑓𝑓(𝑦𝑦). The values for 𝑦𝑦𝐷𝐷 compare closely to those 
published by Nikjoo et al, Lindborg et al and Anderson et al [37, 38, 51]. The discontinuities at 
100 MeV seen in Fig. 7a), c) and Fig. 8 are due to different energy models in Geant4 DNA 
being applied. For protons with kinetic energy < 100 MeV, the DNABornIonisationModel 
model is used when calculating energy losses due to ionization. For protons with energies > 100 
MeV, the BetheBloch ionization model is used. The calculated 𝑦𝑦𝐷𝐷 values published by Nikjoo et 
al at 100 MeV and 200 MeV are 1.8 keV/µm and 0.5 keV/µm, respectively [37]. The 100 MeV 
𝑦𝑦𝐷𝐷 for this work was calculated to be 2.13 keV/µm, while the 200 MeV 𝑦𝑦𝐷𝐷 was calculated to be 
2.8 keV/µm. A 𝑦𝑦𝐷𝐷 value of about 3 keV/µm at 100 MeV was published by Lindborg et al [38]. 
The 𝑦𝑦𝐷𝐷 values in this work compare closely to those published by Nikjoo et al and Lindborg et 
al at 100 MeV, but there is a large difference at 200 MeV between this work’s 𝑦𝑦𝐷𝐷 and the 𝑦𝑦𝐷𝐷  
published by Nikjoo et al. Tsuda et al published a study of the microdosimetry of proton, helium 
and silicon ion beams where they compared measured 𝑦𝑦𝐷𝐷  to those calculated by the Monte 
Carlo code PHITS [52]. They measured 𝑦𝑦𝐷𝐷 of a 160 MeV proton beam to be about 2.5 keV/µm, 
calculated 𝑦𝑦𝐷𝐷 with PHITS to be about 1.98 keV/µm. This work calculated 𝑦𝑦𝐷𝐷  to be 2.56 
keV/µm at 160 MeV. Jing Chen published a series of microdosimetry calculations of proton 
beams and her 𝑦𝑦𝐷𝐷 values at 500 keV, 2 and 5 MeV closely matched those calculated in this 
work [53]. However, at 100 MeV and 200 MeV, Chen calculated 𝑦𝑦𝐷𝐷 at ~5 keV/µm and 4 
keV/µm, respectively. The 𝑦𝑦𝐷𝐷 calculated by this work is 2.1 keV/µm at 100 MeV and 2.8 




Beyond the discontinuity at 100 MeV, the 𝑦𝑦𝐷𝐷 values calculated in this work are similar 
to those calculated in previous works, and similar to those values measured with 
microdosimeters such as in Anderson et al [51]. The relationship between LETD and 𝑦𝑦𝐷𝐷 is 






, where 𝛿𝛿2 is the weighted energy loss per collision and 𝑑𝑑 is the diameter of the domain [31]. 
Therefore a linear relationship between LETD and 𝑦𝑦𝐷𝐷 is expected.  
4.5 MKM fitting of experimental RBE data 
The MK model was applied to the experimental RBE data and the fitting results are 
shown in Figs. 10-12. Similar to the generic RBE model, the MK model fit the Guan and Bronk 
et al. data poorly (Fig. 10). The MK model performed well with the Patel and Bronk et al data 
shown in Fig. 12, as well as both AGO1522 data sets, and the U87 SOBP data from Chaudhary 
et al in Fig. 11. Interestingly, the MKM was able to model the fine structure from the SOBP 
experiments from Chaudhary et al, where RBE varies more nonlinearly with LETD than in the 
pristine Bragg peak experiments. In those experiments the first three RBE points and last three 
RBE points seem to be linearly related, but with different slopes. The MK model was able to 
capture this fine structure better, most likely due to the fluence-weighted method to calculate 𝑦𝑦𝐷𝐷 
proposed in Eq. 18 and Eq. 19. This may also be evidence that 𝑦𝑦𝐷𝐷 is a better metric for 
biological effect than LETD. This result should encourage further study of the MKM for clinical 
adoption as all proton plans are designed using SOBPs, not pristine Bragg peaks. The best-fit 𝑟𝑟𝑑𝑑 
values are shown for each experiment in Figs. 10-12. In this work, 𝑟𝑟𝑑𝑑 varied between 0.202 µm 
and 0.461 µm. Other authors have published their 𝑟𝑟𝑑𝑑 values for various cell lines. Kase et al 




µm, 0.34 µm, and 0.35 µm [54]. Mairani et al published an 𝑟𝑟𝑑𝑑 value of 0.300 µm for proton and 
helium beams [55]. The 𝑟𝑟𝑑𝑑 in this work are thus consistent with previously published values.  
The data presented by Guan and Bronk et al and Patel and Bronk et al used the same cell 
line, H460. The Patel and Bronk et al data showed a much more linear relationship between 
RBE and LETD than the Guan and Bronk et al data, however. The 𝑟𝑟𝑑𝑑 for each experiment was 
very different as well. For the Guan and Bronk et al study, the best fit 𝑟𝑟𝑑𝑑 was 0.323 µm; for the 
Patel and Bronk et al data, the best fit 𝑟𝑟𝑑𝑑 was 0.426 µm. As Table 9 shows, both of these values 
fall outside of the other’s 95% confidence interval. These large differences in 𝑟𝑟𝑑𝑑 are attributed to 
the different Monte Carlo settings applied to simulations between the two groups, and the 
different methods by which surviving cell colonies were counted between the two studies. Patel 
and Bronk et al discuss this Monte Carlo settings issue in detail in their work [19].  
4.6 AIC analysis of generic RBE model vs. MK model 
Overall the AIC analysis indicated the generic RBE model fit the data best in five 
experiments while the MKM fit the data better in two experiments. However, neither model fit 
the Guan and Bronk et al data well, so the AIC analysis indicates only a weak preference for the 
generic RBE model over the MK model. Based on the AIC analysis there is no clear evidence 
that MKM models RBE better than a generic, LETD-based model, for this dataset. Both models 
performed well in some experiments, and both models performed poorly in others. This work 
has shown that MKM can be applied to proton RBE studies and can accurately model RBE 
based on the 𝑦𝑦𝐷𝐷 calculation method presented in section 2.3.3. However, the MK model does 
not show a clear superiority in fitting the RBE data as compared to the generic RBE model. 
Therefore it is concluded that there is not enough evidence to support moving away from LETD 
based proton RBE models that model RBE as a linear function of LETD. There may be some 




present, both the generic RBE model and MKM model provide a sufficiently accurate model of 
RBE, even if the underlying RBE model is actually more complex.  
4.7 MKM Optimization in matRad 
Before proceeding with MKM optimization, a radiation oncologist evaluated the std_opt 
plan and gave feedback until the plan was realistic enough to begin variable RBE optimization. 
The DVH for the std_opt plan is shown with dashed lines in Fig. 14 and summarized in Table 
10. The MK model predicted RBE < 1. 1 throughout most of the brainstem, which led to a 
decrease in RWD for the brainstem in the std_opt_MKM_calc plan. The RBE in the GTV and 
CTV varied greatly between ~1.0-1.4, with hot and cold RBE spots as shown in Fig. 15. Despite 
hot and cold RBE spots, there was very similar RWD coverage between the std_opt and 
std_opt_MKM_calc plans: 88.0 % of the GTV got 54 Gy(RBE) in the std_opt plan, and 87.7% 
of the GTV got 54 Gy(RBE) in the std_opt_MKM_calc plan. The RWD when calculating RBE 
with the MKM was slightly lower in the spinal cord as well. There were hot spots in the CTV 
and just outside the CTV in excess of 70 Gy(RBE) that are shown in Fig. 16.  
That the RWD in the brainstem decreased when using the MK model is counter to 
previous experience with proton irradiation close to the brainstem, where evidence of RBE > 1.1 
in the brainstem has been shown [14, 15]. This could be attributed to the choice in 𝑟𝑟𝑑𝑑 for the 
brainstem during RBE optimization. 𝑟𝑟𝑑𝑑 was set to 461 nm, but setting it to a smaller value such 
as 420 nm (at the lower limit of its 95% confidence interval in the U87 SOBP data in Table 9) 
would increase the RBE, as 𝑟𝑟𝑑𝑑 is in the denominator when calculating RBE according to Eq. 14. 
Based on clinical experience in irradiating the brainstem it may be more appropriate to select an 
𝑟𝑟𝑑𝑑 such that the RBE in the brainstem is ~1.1, and not as low as is shown in Fig. 15.  
The brain hotspot in Fig. 16 was removed during the MKM optimization process as 




modulated to decrease the RWD hotspot. One of the most interesting results of the MKM_opt 
plan is the increase of physical dose to some regions of the brainstem, shown in Fig. 20 a. Due 
to the lower RBE (<1.1) in the brainstem, this led to a lower RWD in the brainstem in the 
std_opt_MKM_calc plan, which gave the optimizer freedom to increase physical dose to the 
brainstem in the MKM_opt plan. Table 11 shows if the physical dose from the MKM_opt plan 
is recalculated using the RBE=1.1 model, the RWD to 0.1cc of the brainstem increases from 
56.0 to 59.1 Gy(RBE). This plan would most likely be rejected for having too high of dose to 
the brainstem, in addition to having significantly lower GTV and CTV coverage at 54 Gy(RBE). 
Without significant evidence of the superiority of using these settings for the MK model, it is 
unlikely to be adopted, as the recalculated RWD using the RBE=1.1 model shows a higher dose 
to the brainstem than is clinically acceptable. Physical dose was decreased in the hotspot region 
shown in Fig. 16 b and 17a, ~6-7 Gy(RBE), shown in Fig. 20 b. Fig. 20a shows the physical 
dose was modulated in the same slice shown in Fig. 15, and is consistent with the dose 
modulation seen elsewhere in the MKM_opt plan.   
The MKM_opt plan resulted in better GTV coverage (94.0% getting at least 54 
Gy(RBE) as compared to 87.7% in the std_opt_MKM_calc plan), despite decreasing the 
physical dose in some regions of the GTV. The RWD to the spinal cord also slightly decreased 
in the MKM_opt plan. The RWD to 0.1cc of the brainstem was increased from 55.8 Gy(RBE) to 
56.0 Gy(RBE) in the MKM_opt plan as well. That the RWD increased in the brainstem is a 
result of increasing physical dose to the brainstem, despite a decrease of the 𝑦𝑦𝐷𝐷 shown in Fig. 
19. The increased physical dose in the brainstem is shown in Fig. 20, while the modulation of 
𝑦𝑦𝐷𝐷 between the two plans is demonstrated in Fig. 19.  
A useful exercise is to analyze the physical dose distribution given by the MKM_opt 




11. GTV coverage at 54 Gy(RBE) drops from 94.0% to 77.5%, and GTV EUD decreases from 
58.3 Gy(RBE) to 55.9 Gy(RBE). The CTV coverage deceases significantly as well. The doses 
to the brainstem and spinal cord also increase when the MKM_opt RWD is recalculated with 
RBE=1.1. The DVH in Fig. 21 shows that by assuming the given MKM parameters during 
optimization, the resulting plan may be overdosing the brainstem and significantly reducing 
CTV and GTV coverage.  
There are a number of issues to be aware of with the MKM optimization algorithm written 
into matRad in this work that need to be addressed before clinical implementation. They 
include: 
1) The high RBE values seen in experiments such as in Refs. 17-19 occur only along the 
distal falloff region of the Bragg peak or SOBP. The rapidly rising RBE occurs within a 
fraction of a millimeter, in the falloff region where the dose drops dramatically across 
that same distance. Voxel sizes in patient planning CTs are on the order of 1 mm, so 
these high RBE regions are likely to be lost due to volume averaging.  
2) In this project, the 𝑟𝑟𝑑𝑑 for specific tissues were assumed to be the same as they are for the 
U87 glioma and AGO1522 fibroblast data from Ref. 17 fit for the MK model presented 
in this work. These values have not been clinically validated, although a similar  𝑟𝑟𝑑𝑑 value 
(320 nm) was used by Inaniwa et al in their study for using MKM in the research version 
of their carbon ion treatment planning system [43]. Based on RBE values in the 
brainstem much less than 1.1, it is appropriate to reevaluate the 𝑟𝑟𝑑𝑑 value for the 
brainstem. 𝑟𝑟𝑑𝑑 should be a smaller value, perhaps around 420 nm. The result of 




translating the fitting parameters of RBE experiments directly into a TPS. All 
radiobiological parameters should be fully evaluated before clinical implementation.  
3) The 𝛼𝛼0 values used for RBE optimization marked a change from the method of using 𝛼𝛼𝑥𝑥 
laid out in Chapter 2.2-2.4. This reflects a changing concern over the course of this 
multi-year project that RBE experiments widely differ in the reference radiation used. 
For instance, in the RBE data in Ref. 17, 225 kVp x-rays are used and in Ref. 18 and 19, 
Cs-137 irradiation is used. In the method laid out by Frese et al in Ref. 45, 𝛼𝛼0 has been 
adjusted from 𝛼𝛼𝑥𝑥 to remove dependence on LET. Using 𝛼𝛼0 is most consistent with the 
theory of the MKM, and so is used for treatment plan optimization. However the 
difference between 𝛼𝛼0 and 𝛼𝛼𝑥𝑥 in Frese et al’s data are small and the difference in RBE 
between the two values would be negligible.  
4) Using a RBE defined as the dose required to reach a clonogenic cell survival fraction of 
10% may not be the most accurate representation of RBE effects in vivo. Other RBE 
endpoints such as intestinal crypt cell regeneration, single or double strand break 
induction, foci of DNA repair proteins and chromosome aberrations have all been used 
as endpoints to model RBE [56, 57]. Overall, the alternate endpoints do not disagree 
with the current RBE=1.1 model, although some selected endpoints did show 
considerable differences. Other clinically-relevant endpoints include standardized 
cognitive tests, inflammation and late tissue reactions, and these are not addressed by the 
MK model [42].  
5) When creating the patient treatment plan, the exact beam geometry (beam angle and 
couch angle) the patient was treated with was used for IMPT optimization. These may 




6) The method to calculate 𝑦𝑦𝐷𝐷𝑚𝑚𝑚𝑚𝑥𝑥 is very similar to using LETD, whose drawbacks have 
been written about extensively [11, 12]. As proposed in this work, calculating  𝑦𝑦𝐷𝐷 based 
on the proton energy spectrum may be a more accurate way to model biological effect. 
However with the present computational and software resources, it is not feasible to 
compute the proton energy spectrum in every voxel in the planning CT fast enough to be 
useful for optimization. GPU-based Monte Carlo systems may be fast enough for clinical 
implementation, however [58].  
7) Neither of the two optimized treatment plans (std_opt or MKM_opt) were robustly 
optimized, either for physical dose or biologically. Including robust optimization would 
greatly increase the optimization time.  
8) The IMPT plans (std_opt and MKM_opt) were probably not the best IMPT plans that 
could be created, due to the author’s inexperience with treatment planning. However, the 
purpose of comparing a standard RBE=1.1 treatment plan to one with variable RBE is 
meant to illustrate the possible benefits of including variable RBE in optimization; 
namely enhanced GTV coverage and increased sparing of normal tissues. MatRad lacks 
many features of commercial treatment planning systems that users can utilize to fine 
tune the dose distribution of plans. With more time and skill, more clinically realistic 
plans could be created.  
9) Despite the large discontinuity in 𝑦𝑦𝐷𝐷 at 100 MeV (Figs. 8 and 13), this discontinuity will 
have a minor effect on the RBE calculation in matRad. When taking the case of 
predicting RBE in H460 cell line using MKM, 𝛼𝛼𝑥𝑥= 0.29 Gy-1 and 𝛽𝛽𝑥𝑥= 0.083 Gy-2. By 
taking two 𝑦𝑦𝐷𝐷 values of 0.5 keV/µm and 2.8 keV/µm and inputting those parameters into 




RBE = 1.013. When 𝑦𝑦𝐷𝐷 = 0.5 keV/µm, RBE = 1.073. So even though 𝑦𝑦𝐷𝐷 changes by a 
factor of almost six, RBE changes only by about 6%. This is a result of the MKM 
assumption of the insensitivity of 𝛼𝛼𝑝𝑝 to changes at low 𝑦𝑦𝐷𝐷 values, from Eq. 14. If the 
disagreement between 𝑦𝑦𝐷𝐷 were to occur at lower energies, where 𝑦𝑦𝐷𝐷 might be 10 vs 60 
keV/µm, the resulting RBE values would be 1.27 and 2.96, respectively. However, the 
discrepancy is at high energy and relatively low 𝑦𝑦𝐷𝐷 only. Thus it can be concluded that 
despite the large discontinuity in 𝑦𝑦𝐷𝐷 values as a result of different physics lists applied to 
Geant4 DNA, this creates a negligible change in RBE values during treatment planning 
in matRad.   
10) An issue with the implementation of the biological optimization algorithm implemented 
into matRad is the length of time and computational resources it took to create the 
MKM_opt plan. Starting from the result of the std_opt_MKM_calc plan, a biologically 
optimized plan took ~17.2 hours to run, and required up to 104 GB of memory. If the 
plan has to be fine-tuned to be accepted for treatment, the plan will need to be optimized 
several times. However this could be somewhat mitigated by optimizing the code for 
speed, by modifying it to utilize GPU technology, or Matlab’s multithreading capability.  
Despite these drawbacks however, the RBE optimization algorithm was able to take RWD 
hot spots in normal tissue and modulate the physical dose and 𝑦𝑦𝐷𝐷 to create a superior plan in 
MKM_opt, compared to the std_opt_MKM_calc plan, in terms of GTV coverage while still 
adhering to OAR dose constraints. Fine tuning the parameters for 𝑟𝑟𝑑𝑑, 𝛼𝛼𝑥𝑥 and 𝛽𝛽 to more 
clinically-realistic values may lead to a decrease in the superiority of the MKM_opt plan, but 
there may still be some room for improvement over plans optimized using the static RBE=1.1 




The AAPM TG-256 report summarizes the current state of proton RBE research [57]. One 
of the conclusions of the report is that based on current uncertainties in modeling RBE in 
normal tissues and tumors, the adoption of a clinical RBE model is premature. The RBE 
optimization algorithm presented here does not solve the uncertainty issues presented in TG-
256, but it does mirror the conclusion of the report, that it is theoretically possible to use an 
RBE model in treatment plan optimization that decreases the RWD to critical structures while 
increasing the RWD to the GTV.    
There are other methods to incorporate RBE into the optimization process that are short of a 
full RBE model such as the MKM. The LET distribution can be optimized to put high LET 
regions of the beam into the GTV and CTV, and push the low LET regions into normal tissues 
without significantly changing the physical dose distribution [59]. Another method is to use an 
LET-weighted dose model that models RBE as a function of LET [60]. Others have also 
proposed introducing track-end objectives into optimization, where proton track ends are 
terminated preferentially in the target and LET in normal tissues is decreased, without changing 
the dose to the target [61]. These approaches can take into account the variation in RBE with 
LET while avoiding the more serious uncertainties that currently plague a clinical 







Chapter 5: Conclusion 
 
5.1 Difference between phenomenological models and experimental RBE data 
The hypothesis of Specific Aim One was that phenomenological RBE models will 
underestimate RBE in the Bragg peak and distal falloff region by 20% or more. In total, three 
RBE models were applied to RBE datasets and as a result, 93 predictions about RBE were made 
by phenomenological models. Of these 93 RBE predictions, 43 model predictions underestimate 
RBE by 20% or more. There is a wide range in quality of model fitting to the experimental data. 
For instance, the U87 cell line from Chaudhary et al is modeled well by all phenomenological 
models while the AGO1522 cells from the same study are poorly modeled by the models. The 
phenomenological models fit the experimental data of Patel and Bronk et al well, but not the 
data presented by Guan and Bronk et al, even though both studies utilized the same cell line. As 
a result of these findings, the hypothesis of Specific Aim One is accepted. In nearly half of the 
RBE data points, phenomenological RBE models underestimate experimental RBE by more 
than 20% in the Bragg peak and distal falloff region.  
5.2 Comparing the MK model to a generic LETD based RBE model 
In Specific Aim Two, the hypothesis was that the proposed method to calculate 𝑦𝑦𝐷𝐷 and 
input into the microdosimetric kinetic model would predict RBE at all experimental points 
within experimental uncertainties. As shown in Figs. 10-12 the MK model was unable to model 
RBE within experimental uncertainties in all experiments. Thus the hypothesis of Specific Aim 
Two is rejected. A goal of Specific Aim Two was to determine the optimal fitting parameters for 
the MKM. The optimal fitting parameters found for this work are similar to those published by 





5.3 Creating biologically-optimized treatment plans with matRad 
The goal of Specific Aim Three was to implement a variable RBE optimization 
algorithm into matRad to create biologically optimized IMPT plans, and to determine if such an 
algorithm can create plans that will both increase target coverage while sparing OARs. The 
treatment plan example demonstrates that the RBE optimization algorithm was implemented 
successfully, and that biologically optimized IMPT plans can, in theory, be superior to plans 
optimized using the RBE=1.1 model. The advantage of these biologically optimized plans is 
slight, however, and a number of assumptions have been made. These assumptions have to be 
evaluated through clinical trials before being adopted for widespread use. However, this work 
has shown that in theory, biologically optimized IMPT plans can be superior to conventionally 
optimized plans that assume a constant RBE of 1.1 Therefore this aim is completed 
successfully.  
5.4 Future directions 
There are a number of improvements and continuations of this work. The question of 
whether or not RBE is a linear function of LETD or 𝑦𝑦𝐷𝐷 is still unanswered, and more 
experiments are needed to answer this question. High precision RBE measurements such as 
those in Refs. 17-19 and proposed by Guan et al [62] will shed light on the RBE-LET 
relationship. Modeling RBE with the MK model can serve as a test of the linearity of RBE as 
well. The work presented here could also be expanded to other cell lines, and cells that have 
already been studied with MKM such as V79, T1 and HSG to determine the variability of 𝑟𝑟𝑑𝑑 in 
different experiments for the same cell line, as has been done with H460 in this work. The 
method to compute 𝑦𝑦𝐷𝐷 can also be expanded into heavier ions such as carbon and helium, and 
RBE could be modeled in a similar way to this work. For heavier ions, a saturation correction 




A very promising research area is the biological optimization of treatment plans. This is 
a topic with considerable interest for proton therapy, but is underdeveloped. Future work could 
adapt this RBE calculation method into a commercial TPS and use that to do a more in-depth 
comparison of treatment plans using variable RBE and constant RBE of 1.1 One assumption 
made in the RBE calculation in matRad is the appropriateness of dose averaging of 𝑦𝑦𝐷𝐷 from 
different pencil beams. The RBE calculated via the algorithm implemented into matRad should 
be compared to a Monte Carlo simulation of the proton energy spectra in each voxel, where 𝑦𝑦𝐷𝐷 
is calculated from Eq. 18 and Eq. 19. This would highlight differences between the two 
calculation methods and may provide insight as to the drawbacks of calculating RBE via the 
MK model and Eq. 26.  A fuller assessment of the tissue-specific MKM parameters for 𝑟𝑟𝑑𝑑, 𝛼𝛼0 
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